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Background: Knee osteoarthritis (OA) is one of the leading causes of disability within the adult population. Current
treatment options for OA of the knee include intra-articular (IA) hyaluronic acid (HA), a molecule found intrinsically
within the knee joint that provides viscoelastic properties to the synovial fluid. A variety of mechanisms in which
HA is thought to combat knee OA are reported in the current basic literature.
Methods: We conducted a comprehensive literature search to identify currently available primary non-clinical basic
science articles focussing on the mechanism of action of IA-HA treatment. Included articles were assessed and
categorized based on the mechanism of action described within them. The key findings and conclusions from each
included article were obtained and analyzed in aggregate with studies of the same categorical assignment.
Results: Chondroprotection was the most frequent mechanism reported within the included articles, followed by
proteoglycan and glycosaminoglycan synthesis, anti-inflammatory, mechanical, subchondral, and analgesic actions.
HA-cluster of differentiation 44 (CD44) receptor binding was the most frequently reported biological cause of the
mechanisms presented. High molecular weight HA was seen to be superior to lower molecular weight HA
products. HA derived through a biological fermentation process is also described as having favorable safety
outcomes over avian-derived HA products.
Conclusions: The non-clinical basic science literature provides evidence for numerous mechanisms in which HA
acts on joint structures and function. These actions provide support for the purported clinical benefit of IA-HA in
OA of the knee. Future research should not only focus on the pain relief provided by IA-HA treatment, but the
disease modification properties that this treatment modality possesses as well.
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Although osteoarthritis (OA) of the knee is most often a
slowly progressive joint disorder, it is one of the leading
causes of disability of the adult population [1]. Knee OA,
a disease of the entire joint, is characterized by joint
pain, cartilage degeneration, and an increase in dis-
ability [2]. The progressive nature of OA leads to de-
creased knee function, affecting an individual’s ability
to perform daily activities [3]. Knee OA also nega-
tively impacts socioeconomic factors, as the associated* Correspondence: journals@royaltman.com
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and early retirement [4].
Since there is no established disease modifying agent for
OA, there are many options for the treatment of knee
OA. Among the pharmacologic therapies, non-steroidal
anti-inflammatory drugs (NSAIDs) and intra-articular
(IA) corticosteroid injections are most commonly pre-
scribed [5]. These options have inherent limitations, as
NSAIDs have potentially serious adverse events associated
with their use [6], and IA corticosteroid injections often
provide a relatively short period of effective relief [7]. Al-
though corticosteroid injection generally has a positive
safety profile, it has been shown to cause a transient in-
crease in blood glucose, which may be a concern foris distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Search strategy
MEDLINE and EMBASE – 1470 articles PubMed – 1395 articles
1. Hyaluronic acid[title] 1. Hyaluronic acid[title]
2. Hylan[title] 2. Hylan[title]
3. Hyaluronan[title] 3. Hyaluronan[title]
4. Viscosupplementation[title] 4. Viscosupplementation[title]
5. 1 or 2 or 3 or 4 5. 1 or 2 or 3 or 4
6. Osteoarthrit*.mp 6. Osteoarthrit*
7. Arthrit*.mp 7. Arthrit*
8. Joint pain.mp 8. Joint pain
9. 6 or 7 or 8 9. 6 or 7 or 8
10. Effect*.mp 10. Effect*
11. Mechanism*.mp 11. Mechanism*
12. 10 or 11 12. 10 or 11
13. 5 and 9 and 12 13. 5 and 9 and 12
*denotes the use of the truncation function within the database
Altman et al. BMC Musculoskeletal Disorders  (2015) 16:321 Page 2 of 10diabetic patients [8]. IA injection of hyaluronic acid (HA)
is another treatment option for knee OA pain. HA is
nearly ubiquitous in the body, and is a molecule found in-
trinsically within the knee joint where it provides visco-
elastic properties to synovial fluid [9]. As OA progresses,
natural HA concentration and the distribution of HA
within the joint shifts towards lower ranges of HA mo-
lecular weight, leading to a degradation of the mechan-
ical/viscoelastic properties of the endogenous synovial
fluid [2, 10, 11]. Lower ranges of molecular weight distri-
butions have also been shown to be strongly correlated to
pain [11]. IA-HA administration has aimed to restore this
decline in HA concentration and the average molecular
weight distribution within the OA knee [9].
IA-HA has been proposed to have many therapeutic
mechanisms of action in the OA knee, including shock
absorption, joint lubrication, anti-inflammatory effects,
chondroprotection, proteoglycan synthesis, and cartilage
matrix alterations [2]. The correlation between these
various effects has created a better understanding of
how IA-HA treatment could provide therapeutic effects
for patients with knee OA [12]. There is also evidence
suggesting distinct mechanism of action differences be-
tween HA products of varying molecular weight. That
is, higher molecular weight (HMW) HA has been re-
ported to provide greater anti-inflammatory and pro-
teoglycan synthesis effects, as well as joint lubrication
and viscoelasticity maintenance [9, 13]. There also ap-
pears to be evidence of variable safety profiles be-
tween HA derived through a biological fermentation
process (Bio-HA) and avian-derived HA (AD-HA), as
AD-HA has the potential for local IA reactions [14, 15].
We aim to summarize the mechanisms of action for
IA-HA treatment of knee OA described in the
current literature in order to determine the validity of
the above mechanisms of action. We will systematic-
ally assess and outline the defined mechanisms in which
HA may provide a therapeutic benefit, while analyzing re-
ported distinction between product characteristic-
dependent effects of IA-HA treatment.
Methods
Literature search
We conducted a comprehensive literature search using
the MEDLINE, EMBASE, and PubMed databases
(Table 1). The search was conducted on May 4th, 2014.
The inclusion criteria followed throughout the screening
process were as follows: 1) Articles describing the mech-
anism of HA treatment for OA, 2) Articles focused on
OA of the knee, and 3) Primary non-clinical basic science
articles focussing on “viscosupplementation”/HA treat-
ment. Articles that were published before 1990 or were
not published in English were excluded from the study. If
multiple studies outlining similar results were publishedby the same author, only the most recent study was
accepted for inclusion.Data abstraction
Included articles were assessed and categorized based on
the mechanism of action described within them. Single
articles were included in multiple categories if they ana-
lyzed more than one mechanism of HA action within
their study design. The mechanism categories utilized in
the data abstraction process were: chondroprotection, al-
terations in proteoglycan and/or glycosaminoglycan
(GAG) synthesis, anti-inflammatory effects, mechanical
modifications, alterations in subchondral bone, and
analgeisic effects.Data analysis
The key findings and conclusions from each included
article were obtained and analyzed in aggregate with
studies of the same assigned category. The results pre-
sented have been derived through interpretation of com-
mon and consistent mechanism of action presentations
within each aforementioned category.Results
Search strategy
The literature search identified 2,782 potential articles
and, of these, 91 articles met the inclusion criteria
(Fig. 1). Thirteen additional articles were retrieved by a
content expert’s hand search of the literature. This re-
sulted in a total of 104 articles included. The conclusions
and key findings of each article were identified within
the aforementioned mechanism categories (Table 2).
Fig. 1 Article screening process
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Sixty-seven of the included articles described chondro-
protective effects of IA-HA treatment [9, 12, 16–80]. IA-
HA has been shown to reduce chondrocyte apoptosis,
while increasing chondrocyte proliferation [19, 20]. There
are multiple observed effects of IA-HA treatment that
produce chondroprotection, many of which are results of
HA binding to cluster of differentiation 44 (CD44)Table 2 Key mechanisms of action reported by the included articles
Mechanism of action Number of articles % of
Chondroprotective 67 64.42
Proteoglycan/Glycosaminoglycan synthesis 22 21.15
Anti-inflammatory 21 20.19
Mechanical 10 9.61
Subchondral bone 8 7.69
Analgesic 6 5.76receptors. HA binding to CD44 inhibits interleukin (IL)-
1β expression, leading to a decline in matrix metallopro-
teinase (MMP) -1, 2, 3, 9, and 13 productions [32, 34].
This binding to CD44 has been shown to be of greater ef-
fect for higher MW HA products [21]. HA also binds to
the receptor for hyaluronan mediated motility (RHAMM),
which is thought to aid in chondroprotection in addition
to CD44 binding [34]. The inhibition of IL-1β expression
through CD44 binding is carried out through induction of
mitogen-activated protein kinase phosphatase (MKP) -1: a
negative regulator of IL-1β [43]. This inhibition of various
MMPs impedes catabolic enzyme activity within the joint
cartilage [59]. HMW HA was shown to have a greater ef-
fect in the inhibitory action of MMP production [21], al-
though these results are unclear, as another study has
demonstrated the favourable MMP inhibitory effect of
lower molecular weight (LMW) products [72].
Chondrocyte apoptotic events are further decreased by
HA-CD44 binding through the reduction of a disinte-
grin and metalloproteinase with thrombospondin mo-
tifs (ADAMTS) expression [38]. These peptidases are
involved in the cleavage of important synovial com-
ponents, including aggrecan, versican, and brevican
[81, 82]. Various ADAMTS expression has been
shown to decrease as a result of HA-CD44 binding,
providing an additional mode of chondroprotection
for IA-HA treatment [36, 38, 43]. The production of
reactive oxygen species (ROS), such as nitric oxide
(NO), results in degeneration of cartilage through in-
creased chondrocyte apoptosis [33]. IA-HA treatment
demonstrated a reduction in IL-1β-induced oxidative
stress, through inhibition of NO production within
the synovium [48, 57]. Additional results of CD44-
HA binding resulting in chondroprotective effects men-
tioned in the current literature include reduction of pros-
taglandin E2 (PGE2) synthesis [42, 46, 61], and increased
heat shock protein 70 (Hsp70) overexpression [25, 70].
These effects similarly provide therapeutic benefit through
reduction of chondrocyte apoptosis. It is important to
note that HMW HA products demonstrated greater in-
hibition of PGE2 expression than LMW comparators in a
comparative study, resulting in greater chondroprotective
effects [61].included articles References
% [9, 12, 16–80]
% [27, 42, 44, 48, 62, 69, 83–98]
% [13, 20, 21, 25, 27, 52, 54, 55, 68, 72, 96, 97, 99–107]
% [41, 49, 86, 108–114]
% [23, 31, 32, 45, 115–118]
% [76, 80, 119–122]
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Twenty-two of the identified studies reported on the en-
hanced proteoglycan and glycosaminoglycan synthesis re-
lated to IA-HA treatment [27, 42, 44, 48, 62, 69, 83–98].
As OA progresses, intrinsic proteoglycan and GAG con-
centrations decline within the cartilage. Results demon-
strated that IA-HA treatment stimulated proteoglycan
synthesis, delaying the progression of OA [69, 88]. Aggre-
can is the primary proteoglycan within articular cartilage,
and IA-HA treatment is shown to both suppress aggrecan
degradation, as well as promote intrinsic aggrecan devel-
opment [62, 93]. IA-HA treatment is shown to mobilize
newly synthesized proteoglycan to the outer chondrocyte
matrix, potentially providing protection from degradation.
Extrinsic HA promoted movement of newly synthesized
proteoglycan from the cell-associated matrix to the
further-removed matrix in an alginate gel model, which
suggests that IA-HA could provide therapeutic relief of
OA by strengthening the interterritorial cartilage matrix
[92]. A marker of proteoglycan synthesis, sulphate (35SO4 ),
is seen to be increasingly incorporated within chondro-
cytes after HA introduction [87]. The biological pathway
in which HA alters aggrecan levels is shown to be through
CD44 and intercellular adhesion molecule (ICAM)-1
binding effects [62]. HMW HA was shown by one study
to provide a greater effect of proteoglycan synthesis than
LMW HA through stimulation of the insulin-like growth
factor (IGF)-1 pathway [89]. IA-HA treatment is also
shown to increase endogenous GAG production. IA-HA
treatment not only supplemented the synovium with HA,
it promoted intrinsic production of HA [27].
Anti-inflammatory
Twenty-one of the identified studies reported on the
anti-inflammatory effects of IA-HA treatment [13, 20,
21, 25, 27, 52, 54, 55, 68, 72, 96, 97, 99–107]. IL-1β is
known to demonstrate pro-inflammatory effects, and the
aforementioned suppression of IL-1β expression by HA
provides anti-inflammatory effects [52]. IL-1β is a key
mediator in the anti-inflammatory effects of HA, and is
regulated through HA-CD44 binding [59, 104]. IL-1β
suppression results in a down-regulation of MMPs as
previously mentioned, which also aids in the anti-
inflammatory effect of HA [52]. Further suppression of
pro-inflammatory mediators IL-8, IL-6, PGE2, and tumor
necrosis factor (TNFα) provides anti-inflammatory ef-
fects of IA-HA treatment [13, 21]. The relation between
Toll-Like Receptors (TLR) and an inflammatory re-
sponse is demonstrated as HA degradation products in-
duced an inflammatory response through CD44 and
TLR interaction. This pro-inflammatory response from
HA degradation product binding to TLR and CD44 re-
ceptors results in increased Nf-kB, IL-1β, TNFα, IL-6,
and IL-33 production [105]. HMW HA has beendemonstrated to suppress numerous inflammatory me-
diators through TLR 2 and 4 binding, including TNF-α,
IL-1-β, IL-17, MMP-13 and inducible nitrogen oxide
synthase (iNOS) [106]. A direct correlation between mo-
lecular weight and anti-inflammatory effects has demon-
strated larger effects of PGE2 and IL-6 inhibition for
HMW HA treatment [13]. IL-6 is a pro-inflammatory
cytokine, regulated by nuclear factor kappa-light-chain-
enhancer of activated B cells (Nf-кB). HA binding to
ICAM-1 down regulates Nf-kB, which in turn decreases
the production of IL-6 [21, 104]. HMW HA down regula-
tion of TNFα, IL-1B and IL-8 is an additional contributory
factor to the anti-inflammatory effects provided by HMW
HA [72, 97].
Mechanical
Ten of the included studies described mechanical effects
of HA in the treatment of knee OA [41, 49, 86, 108–114].
The viscous nature of HA treatment is shown to lubricate
the joint capsule, preventing degeneration through de-
creased friction [86]. HA further protects the joint capsule
through beneficial shock absorption effects. HA provides
cushioning to absorb pressure and vibration within the
joint that otherwise may lead to chondrocyte degradation
[41]. Osteoarthritic knees are reported to have higher fric-
tion within the joint space than healthy knees, which is
counteracted by the joint lubrication capabilities that HA
possesses [110]. HMW HA has been demonstrated to pro-
vide a greater effect of friction reduction due to its viscous
properties. The reduction of friction within the joint can
provide therapeutic effects, as the cartilage is protected
from mechanical degradation [111].
Subchondral bone
Eight of the included studies outlined the effects that
IA-HA has on the subchondral bone [23, 31, 32, 45,
115–118]. It previously has been shown that interaction
between subchondral bone osteoblasts and articular car-
tilage chondrocytes in osteoarthritic joints alters
ADAMTS-4/5 and MMP-1, MMP-2, MMP-3, MMP-8,
MMP-9, and MMP-13 expression and regulation, medi-
ated by mitogen-activated protein kinase (MAPK) and
extracellular signal regulated kinase 1 and 2 (ERK 1/2)
signalling pathways [118]. IA-HA also affects the
subchondral bone through suppression of MMP-13 and
IL-6 via CD44 binding, which potentially prevents
abnormal osseous tissue metabolism [116]. The suppres-
sion of MMP-13 expression by IA-HA has been sug-
gested to be a critical factor in the effect on OA
subchondral bone [117]. The effect that IA-HA has on
MMPs, specifically MMP-13, through CD44 binding has
been suggested to inhibit the effects of OA within the
subchondral bone in numerous non-clinical basic sci-
ence investigations [32, 45, 116–118]. HA effectively
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trabecular structure alterations, resulting in greater sub-
chondral bone compliancy. This ultimately is shown to re-
duce the stress put on cartilage during impact loading
[23]. An indication of IA-HA stimulation of cartilage/bone
interface type II collagen turnover is the increase of urine
carboxy-terminal collagen crosslinks (CTX)-II levels ob-
served following IA-HA treatment, which demonstrated
improvement in the osteoarthritic knee [31]. Ultimately,
HA appeared to limit subchondral bone changes that are
characteristic of early OA [115].
Analgesic
Six of the included articles described the analgesic ef-
fects of IA-HA treatment [76, 80, 119–122]. A single in-
jection of HA demonstrated a significant decrease in
pain-associated behaviour within a murine model [119].
One study suggested that HA did not directly bind to
bradykinin receptors, but provided analgesic effects
through interaction with HA receptors and/or free nerve
endings within the joint tissue [121]. HA analgesic ef-
fects have been shown to occur at mechanosensitive
stretch-activated ion channels, where channel activity is
significantly decreased upon HA binding [122]. HMW
HA was shown to decrease mechanical sensitivity of
stretch-activated ion channels, which effectively blocked
the pain response. LMW HA was seen to be less effective
in blocking this response [122]. HA reduces the action of
joint nociceptors, which provides pain reduction within
the joint. Sensitized nociceptive terminals within the joint
tissue are affected by HA concentration, reducing the pain
response exhibited by these terminals [120].
Discussion
Our review of the existing literature provides a general
consensus that IA-HA for knee OA has beneficial effects
through several mechanisms of action; however, the pre-
dominant mechanism in which therapeutic effect is pro-
vided is not clearly understood [2]. In perspective, it is
not clear which of these mechanisms are clinically rele-
vant, as it is appreciated that beneficial mechanisms of
action are not necessarily transferrable to benefit in the
clinical setting. At this time, it is presumed that the clin-
ical benefit of IA-HA in knee OA is due to several con-
current mechanisms of action, instead of any one single
specific mechanism of action.
The majority of exogenous HA remains in the joint
for a few days; however, the clinical therapeutic effects
of HA treatment may be seen for up to 6 months, or
more. This may suggest that IA-HA contains disease
modifying properties, and does not act solely by restor-
ing viscoelastic properties to the synovial fluid [123]. HA
injections may stimulate endogenous production of add-
itional HA by human synoviocytes, aiding in thenormalization of HA distribution within the synovial
fluid [124]. A large number of reports describe CD44
binding as a primary mode in which HA provides action
against knee OA in non-clinical basic science studies.
CD44-mediated effects of IA-HA are shown to contrib-
ute to the potential chondroprotection, proteoglycan/
glycosaminoglycan synthesis, anti-inflammatory, and
subchondral mechanisms. This binding is shown to have
a variety of effects on numerous signalling pathways, all
of which demonstrate some sort of intervention in the
progression of OA [13, 21, 32, 36, 38, 42, 43, 46, 59, 61,
104, 116]. The suppression of IL-1β and IL-6 and subse-
quent effects of this suppression have been suggested to
be a key factor in the therapeutic mechanism provided
by HA-CD44 binding [123]. It is evident that HA-CD44
binding is a major component in the mechanism in
which HA provides therapeutic effect; however, there are
additional mechanisms that provide alternate pathways
for the effectiveness of HA treatment in OA knees, in-
cluding ICAM binding, mechanical improvements at-
tributed to shock absorption and lubrication, an increase
in cartilage/bone interface type II collagen turnover, as
well as analgesic effects through interaction with nerve
endings and joint nociceptors [31, 41, 86, 97, 121, 122].
HA binding to the RHAMM receptor promotes wound
repair, activates pro-migration and invasion functions,
regulates cellular responses to growth factors, and plays
a role in fibroblast migration and motility [125–127].
These results of HA-RHAMM binding are potential fac-
tors involved in the disease modification effects of HA
treatment for OA.
There is evidence which demonstrates that certain in-
trinsic properties of particular IA-HA products may pro-
vide beneficial results in comparison to other IA-HA
products. The most recognized of these intrinsic proper-
ties is molecular weight. Contrary to a previous basic
science review by Ghosh et al., which suggested a poten-
tial benefit of LMW HA in providing rheological prop-
erty restoration over HMW HAs [128], the evidence
within the current review has demonstrated advanta-
geous results for HMW HA treatments. The current re-
view supports the view that HMW HA provides
superior chondroprotective, proteoglycan and glycosami-
noglycan synthesis, anti-inflammatory, mechanical, and
analgesic mechanisms of action [61, 89, 97, 111, 122]. A
study by Huang et al. demonstrated superior anti-
inflammatory effects of HMW HA but superior chon-
droprotective effects of LMW HA; however, these results
regarding chondroprotection are unclear due to lack of
additional evidence within the knee OA basic science lit-
erature [72]. An increased production of inflammatory
cytokines and chemokines, recruitment of inflammatory
mediators, and blood vessel formation have been shown
to be a response to LMW HA below 500 kDa. While the
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vary greatly, it should be noted that, to our knowledge,
all currently available products worldwide have a mo-
lecular weight >500 kDa [129, 130]. An analysis of HA-
CD44 interaction demonstrated that HA size has direct
impact on the affinity in which HA binds to the CD44
receptor [131]. These results demonstrate the capacity
of HMW HA to treat the progression of knee OA
through CD44 binding of HA. These basic science find-
ings are consistent with systematic reviews of clinical tri-
als and comparative studies which have demonstrated
that HMW HA provides greater therapeutic benefit than
LMW HA in the treatment of knee OA [6, 132], al-
though the current literature does not provide consensus
regarding the clinical efficacy difference between low
and high molecular weight HA [133].
Traditionally, HA products had been derived from
avian sources; however, some available products are pro-
duced by biological fermentation. This process avoids
the presence of avian-derived molecules which are sug-
gested to be a potential cause of adverse local reactions
[134]. There is a lack of thorough reporting regarding
the potential of Bio-HA over AD-HA. One study has
suggested AD-HA injection sites may be the cause of
synovitis in their patient group, yet the exact patho-
logical agent is unknown [135]. Results from a second
study also outline the potential for hylan AD-HA to
cause a foreign body giant cell type granulomatous reac-
tion [136]. Research has demonstrated that the flare-ups
associated with hylan injection may be correlated to the
accumulation of hylan or its breakdown products, as in-
jection site flare ups typically do not occur upon first in-
jection [14]. Avian derived proteins have been shown to
be the cause of injection site flare up, as antibodies to
chicken serum protein were present in patients who
demonstrated injection site adverse reaction after being
treated with AD-HA [15]. There is some high-quality
clinical evidence that Bio-HA has a significantly smaller
incidence of injection site adverse events than AD-HA
[134]; however, this is not thoroughly investigated within
the current literature. More comprehensive investigation
of the difference in incidence of injection site adverse
events between Bio-HA and AD-HA from both a basic
science and clinical perspective is needed.
This review has methodological strength in its system-
atic and thorough search of available basic science evi-
dence within multiple databases. The current report also
demonstrates rigor in its presentation of multiple mecha-
nisms in which HA acts, providing evidence on all mecha-
nisms whether comprehensively or infrequently reported
within the current literature. Limitations of the current
study arise due to the subjective classification of included
article mechanism of action key conclusions. Included ar-
ticles may briefly mention alternate mechanisms of action,but were not classified into the corresponding category
because the mentioned alternate mechanism was not a
key result or conclusion of the study. Future research
should analyze the relationship between the various mech-
anisms presented in this report, and clarify the way in
which these mechanisms overlap and may work together
to alleviate symptoms of knee OA. Future research should
also aim to recognize differences between mechanisms ex-
hibited by high and lower molecular weight products, as
well as analyze the safety profile differences between Bio-
HA and AD-HA.
Conclusions
The non-clinical basic science literature provides evi-
dence for numerous mechanisms in which IA-HA may
provide clinical benefit in knee OA. Chondroprotection
is the most frequently reported mechanism, with HA-
CD44 binding being the most frequently reported source
of these effects. IA-HA is also reported to provide
proteoglycan and glycosaminoglycan synthesis, anti-
inflammatory, mechanical, subchondral, and analgesic
effects. There is evidence of favorable results for HMW
HA treatments in comparison to LMW HA. Bio HA is
also demonstrated to provide an advantageous safety
profile over AD-HA, as reports demonstrate the associ-
ation between injection site flare ups and avian-derived
proteins. There are a variety of reported mechanisms in
which IA-HA is demonstrated to treat knee OA, as well
as numerous product characteristics that impact the re-
sults of IA-HA treatment. A thorough understanding of
the variety of mechanisms in which IA-HA provides
beneficial effects within the OA knee, as well as the
characteristic-specific effects of various IA-HA products,
is required to recognize the applicability and appropri-
ateness of IA-HA treatment for knee OA. Future re-
search should not only focus on the pain relief provided
by IA-HA treatment, but the disease modification prop-
erties that this treatment modality may possess as well.
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